Enhanced Collagenase-Based System for Uterine Fibroid Treatment

A novel system and method for treating uterine fibroids, leveraging pH-adjusted buffers, temperature-controlled needles, protease inhibitors, and fibronectin-binding peptides to enhance collagenase efficacy and minimize off-target effects.

The original patent disclosed a method for treating uterine fibroids using purified collagenase. However, the existing approach has limitations, including suboptimal collagenase activity, inadequate tissue penetration, and potential off-target effects. The new inventive concept addresses these limitations by introducing pH-adjusted buffers, temperature-controlled needles, protease inhibitors, and fibronectin-binding peptides to enhance collagenase efficacy and minimize off-target effects.

The enhanced system comprises a collagenase composition with a pH-adjusted buffer to optimize enzymatic activity. The composition is delivered through a temperature-controlled needle to facilitate efficient tissue penetration. Additionally, a protease inhibitor is included to minimize off-target effects. In some embodiments, a fibronectin-binding peptide is added to enhance collagen degradation. The system also includes a biocompatible carrier for sustained release of the collagenase composition. A device for delivering the composition features a catheter with a porous membrane to facilitate localized delivery, and a pressure sensor to monitor injection force. Furthermore, a method for predicting treatment outcomes involves analyzing gene expression profiles of fibroid tissue to identify markers of collagenase responsiveness, and using machine learning algorithms to predict treatment efficacy.

The new claims introduce several novel and non-obvious features, including pH-adjusted buffers, temperature-controlled needles, protease inhibitors, and fibronectin-binding peptides, which collectively enhance collagenase efficacy and minimize off-target effects. These features are not anticipated by the original patent and represent a significant improvement over the existing approach.

Alternative embodiments of the inventive concept include using different pH-adjusted buffers, temperature-controlled needle designs, and protease inhibitors. Additionally, the fibronectin-binding peptide could be replaced with other collagen-binding peptides or molecules. The device for delivering the composition could also be modified to include different types of catheters, needles, or sensors.

The enhanced collagenase-based system has significant commercial potential in the medical device and pharmaceutical industries, particularly in the treatment of uterine fibroids. The target market includes hospitals, clinics, and medical centers specializing in women's health and reproductive medicine.